Methenamine does not cause cancer based on the available evidence. The concern makes sense: methenamine works by breaking down into formaldehyde inside your bladder, and formaldehyde is a known carcinogen when inhaled over long periods. But the way methenamine delivers formaldehyde to your body is fundamentally different from industrial exposure, and multiple animal studies spanning decades have found no increased cancer risk.
Why the Formaldehyde Connection Raises Questions
Methenamine, first introduced as a urinary antiseptic in 1899, is an organic compound that travels to your bladder after you swallow it. Once there, the acidic environment of your urine breaks it down into two byproducts: formaldehyde and ammonia. The formaldehyde is the active ingredient, killing bacteria in the urinary tract. This reaction only happens when urine pH drops below 6, which is why some people take vitamin C alongside methenamine to keep their urine acidic enough.
Formaldehyde is classified as a human carcinogen, but that classification is based on chronic inhalation exposure in occupational settings like factories and embalming facilities. The route of exposure matters enormously in toxicology. Breathing in formaldehyde vapors day after day damages the lining of the nose and throat, which can eventually lead to nasopharyngeal cancer. Swallowing a medication that releases small amounts of formaldehyde locally in the bladder is a very different scenario.
What Animal Studies Found
The carcinogenic potential of methenamine has been directly tested in multiple long-term and lifetime studies across several strains of both rats and mice, all using oral administration. These studies used doses as high as 2.5 grams per kilogram of body weight per day, which is far above what any human would take. The results were consistent: no indication of carcinogenic effects following prolonged exposure to high doses.
Beyond cancer specifically, these studies found no organ toxicity at all. Body weight gain, food consumption, survival rates, organ weights, and tissue examined under the microscope were all unchanged compared to animals that received no methenamine. In other words, even at extreme doses given over the animals’ lifetimes, methenamine didn’t damage tissues or promote tumor growth in any organ.
The Formaldehyde-in-Drinking-Water Study
Germany’s Federal Institute for Occupational Safety and Health conducted a separate risk assessment looking at formaldehyde itself (not methenamine) given to rats in their drinking water over several years. This is relevant because it mimics what happens in the body when methenamine breaks down: formaldehyde contacting internal tissues through ingestion rather than inhalation. The result was no increased tumor incidence in any organ. The institute concluded that formaldehyde formation from methenamine breaking down inside the body “should be of no concern with respect to carcinogenicity.”
Why Bladder Exposure Is Different From Inhalation
The formaldehyde produced in your bladder stays largely contained there. It’s diluted in urine and flushed out when you urinate. Unlike airborne formaldehyde, which contacts delicate respiratory tissue continuously during a work shift, the bladder lining is exposed to relatively low concentrations for limited periods. Your body also produces small amounts of formaldehyde naturally as part of normal metabolism, so your cells have built-in mechanisms to break it down quickly.
Methenamine also converts partially to formaldehyde in the stomach, which can cause nausea or stomach discomfort in some people. But the amounts are small and rapidly metabolized. People with severe kidney failure (filtration rate below 10 ml/min) are advised not to take methenamine because impaired kidneys can’t clear the drug efficiently, potentially allowing toxic levels to build up. For everyone else, the compound passes through the body without accumulating.
Long-Term Use and Safety Profile
Many people take methenamine for months or even years to prevent recurrent urinary tract infections, particularly as an alternative to repeated courses of antibiotics. The OECD’s chemical safety review, which compiled data from multiple studies, found no specific organ toxicity from repeated long-term administration. Clinical studies in populations like kidney transplant recipients have similarly shown no significant changes in kidney function markers during methenamine use.
The drug has now been in continuous clinical use for over 125 years. That unusually long track record provides a kind of real-world safety data that newer medications simply don’t have. No pattern of increased cancer rates has emerged in the population of people who take it, despite the millions of prescriptions written over that time span. While this kind of observational evidence isn’t as rigorous as a controlled trial, the absence of any signal after more than a century of use is meaningful.